These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32308)

  • 1. Use of a physical multi-cell model to confirm theoretical predictions of biphasic structure-activity relationships [proceedings].
    Dearden JC; Patel KD
    J Pharm Pharmacol; 1978 Dec; 30 Suppl():51P. PubMed ID: 32308
    [No Abstract]   [Full Text] [Related]  

  • 2. A theoretical approach to structure-activity relationships. Some implications for the concept of optimal lipophilicity [proceedings].
    Dearden JC; Townend MS
    J Pharm Pharmacol; 1976 Dec; 28 Suppl():13P. PubMed ID: 12286
    [No Abstract]   [Full Text] [Related]  

  • 3. Structure--mutagenicity relationships for chlorinated ethylenes: a model based on the stability of the metabolically derived epoxides.
    Jones RB; Mackrodt WC
    Biochem Pharmacol; 1982 Nov; 31(22):3710-2. PubMed ID: 7181961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parabolic structure-activity relationships: a simple pharmacokinetic model.
    Aarons L; Bell D; Waigh R; Ye Q
    J Pharm Pharmacol; 1982 Nov; 34(11):746-9. PubMed ID: 6129312
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemical structure of mutagens and carcinogens and the relationship with biological activity.
    Benigni R
    J Exp Clin Cancer Res; 2004 Mar; 23(1):5-8. PubMed ID: 15149144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative structure--activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character.
    Kubinyi H
    J Med Chem; 1977 May; 20(5):625-9. PubMed ID: 857018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental verification of the roles of intrinsic matrix viscoelasticity and tension-compression nonlinearity in the biphasic response of cartilage.
    Huang CY; Soltz MA; Kopacz M; Mow VC; Ateshian GA
    J Biomech Eng; 2003 Feb; 125(1):84-93. PubMed ID: 12661200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
    Wilson LY; Famini GR
    J Med Chem; 1991 May; 34(5):1668-74. PubMed ID: 2033592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative structure-activity relationships. VI. Non-linear dependence of biological activity on hydrophobic character: calculation procedures for bilinear model.
    Kubinyi H; Kehrhahn OH
    Arzneimittelforschung; 1978; 28(4):598-601. PubMed ID: 581935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoinformatics for rational discovery of safe antibacterial drugs: simultaneous predictions of biological activity against streptococci and toxicological profiles in laboratory animals.
    Speck-Planche A; Kleandrova VV; Cordeiro MN
    Bioorg Med Chem; 2013 May; 21(10):2727-32. PubMed ID: 23582445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings: Structure-activity techniques in the treatment of antitumor drug data.
    Purcell WP
    Cancer Chemother Rep 2; 1974 Dec; 4(4):41. PubMed ID: 4447931
    [No Abstract]   [Full Text] [Related]  

  • 12. On model building in structure-activity relationships. A reexamination of adrenergic blocking activity of beta-halo-beta-arylalkylamines.
    Unger SH; Hansch C
    J Med Chem; 1973 Jul; 16(7):745-9. PubMed ID: 4146906
    [No Abstract]   [Full Text] [Related]  

  • 13. [MASCA-model of the biochemical-pharmacological drug research / part 5: Structure-activity relationships and MACOVA (author's transl)].
    Mager PP
    Arzneimittelforschung; 1975 Nov; 25(11):1745. PubMed ID: 1243081
    [No Abstract]   [Full Text] [Related]  

  • 14. [MASCA-model of biochemical-pharmacological drug research. Part 6: Structure-activity relationship and bio-oscillations (author's transl)].
    Mager PP
    Arzneimittelforschung; 1975; 25(12):1864-5. PubMed ID: 1243656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical model of dose-activity relationships.
    Franke R; Oehme P; Barth A
    Environ Qual Saf Suppl; 1975; 3():461-66. PubMed ID: 1063665
    [No Abstract]   [Full Text] [Related]  

  • 16. Possibility of analytical application of the partition in aqueous biphasic polymeric systems technique.
    Zaslavsky BY; Miheeva LM; Rogozhin SV
    Biochim Biophys Acta; 1978 Jun; 510(1):160-7. PubMed ID: 667032
    [No Abstract]   [Full Text] [Related]  

  • 17. [MASCA-model of the biochemical-pharmacological drug research. Part 3: Structure-activity relationships and KANORA (author's transl)].
    Mager PP
    Arzneimittelforschung; 1975 Sep; 25(9):1355-6. PubMed ID: 1242657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional structure-activity relationships.
    Marshall GR; Cramer RD
    Trends Pharmacol Sci; 1988 Aug; 9(8):285-9. PubMed ID: 3074545
    [No Abstract]   [Full Text] [Related]  

  • 19. QSAR: quantitative structure-activity relationships in drug design. Proceedings of the 7th European Symposium on QSAR. Interlaken, Switzerland, September 5-9, 1988.
    Prog Clin Biol Res; 1989; 291():1-443. PubMed ID: 2726827
    [No Abstract]   [Full Text] [Related]  

  • 20. Obscure phenomena in statistical analysis of quantitative structure-activity relationships. Part 1: Multicollinearity of physicochemical descriptors.
    Mager PP; Rothe H
    Pharmazie; 1990 Oct; 45(10):758-64. PubMed ID: 2089387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.